ARTICLE | Company News
Astellas, Grunenthal deal
December 15, 2016 11:18 PM UTC
Astellas said that by 2018 it will grant Grünenthal exclusive rights to peripheral neuropathic pain drug Qutenza capsaicin in Europe, the Middle East and Africa. Qutenza is a dermal patch containing 8...
BCIQ Target Profiles